Percutaneous Thoracic Cryotherapy (PTC) for Inoperable Primary Lung Cancer and Metastatic Management
- Estimate the local and distant failure rates after percutaneous thoracic cryotherapy
(PTC) in patients with unresectable primary lung cancer or lung metastases.
- Estimate rates of PTC complications and adverse reactions.
- Determine the correlations between procedural parameters and follow-up imaging
parameters, with the latter being used as surrogates of local and/or distant treatment
OUTLINE: Patients undergo CT-guided percutaneous thoracic cryotherapy over 2 hours under
local or general anesthesia. Grouped cryoprobes are inserted into the tumor, utilizing a
freeze-thaw-freeze cycle, creating cytotoxic temperatures (less than -20°C to -40°C) that
encompass the entire anticipated tumor volume.
Patients undergo positron emission tomography at baseline and after cryotherapy to assess
tumor standard uptake variable.
After completion of study treatment, patients are followed at 1, 3, 6 and 12 months.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Local and distant failure rates by CT scan at 3, 6, and 12 months
Peter J. Littrup, MD
Barbara Ann Karmanos Cancer Institute
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|